MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Invitae Corporation (NYSE:NVTA)
Organization & Developments: Invitae
Parents
Invitae Corporation (NYSE:NVTA)
Children
*Genetic testing and information company which processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients.
*Specializing in genetic diagnostics for hereditary disorders, Invitae’s mission is to make multi-use genetic testing more accessible and affordable than ever before.
*The company is pursuing a strategy over the next several years to aggregate all the world's medical genetic tests (>3,000 known Mendelian inherited conditions) into a single assay at a lower cost than most single gene tests
*The company provides a diagnostic service comprising hundreds of genes for various genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas.
2018: Assessing Invitae's Flub This Weekseekingalpha.com
2018: Invitae - The Next Generation Of Medicine Is Genomics - Invitae (NYSE:NVTA)
2018: Invitae: Buy The Dip - Bret Jensen
2018: Invitae: Growth Continues Unabated_seekingalpha.com
2018: VA_Q--GENETIC TESTING: VISN 22: 6 MONTH INTERIM: 3/26/18
2019: Another Big Quarter For Invitae_seekingalpha.com
2019: Genetic Testing Companies Take DNA Tests To A Whole New Level
2019: Invitae Gets A Boost From A Mega Insurer_seekingalpha.com
2019: Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018
2019: Invitae To Acquire Clear Genetics For Genetic Chatbot Tech_seekingalpha.com
2019: Invitae to buy DNA-counseling chatbot developer Clear Genetics for $50M
2019: VA_65--Invitae Genetics Laboratory Testing
2020: Genetic Testing Behemoth Invitae Rockets 45% On $1.4 Billion Acquisition _ ArcherDX
2020: Invitae sees 2020 sales as high as $330M_seekingalpha.com
2020: Invitae: Exponential Growth In Genetic Testing
2020: Invitae: Things Beyond Volume And COGS To Watch For
2021: Why Invitae's Genomic Solution Will Drive Shares Higher
2022 Invitae Corporation 2022 Q3 - Results - Earnings Call Presentation_seekingalpha.com
2022: Invitae Busted Business Model Offers A Tactical Opportunity_seekingalpha.com
2022: Invitae Likely Hasn't Reached The Bottom Yet_seekingalpha.com
2022: Invitae Stock: Losses And Debt Suggest Bearish Sentiment Is Deserved_seekingalpha.com
2022: Invitae: This Turnaround Could Be Painfu_ seekingalpha.com
2022: With new CEO, Invitae lays off more than 1,000 employees, slims international footprint
2023: First Blood Test for Dozens of Hereditary Cancers Approved by FDA
2023: Invitae aims to regain NYSE compliance after average share price falls below $1
2023: Invitae Corporation (NYSE:NVTA) is a favorite amongst institutional investors who own 68%
2023: Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts
2023: Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships
2023: Invitae Layoffs 2023: What to Know About the Latest NVTA Job Cuts
2023: Invitae stock jumps as FDA clears cancer test (NYSE:NVTA)
2023: Invitae test for hereditary cancers gains FDA de novo nod
2023: Invitae: What Happened At The JP Morgan Health Conference_seekingalpha.com
2024: Genetic Testing Firm Invitae, Backed by SoftBank and Cathie Wood, Files for Chapter 11
2024: Invitae Enters into Agreement with Labcorp for Sale of Business
2024: Invitae plunges amid report it may file for bankruptcy within weeks (update)
2024: Invitae sells reproductive health assets amid liquidity concerns
Organization & Developments: Invitae (Archives 2016-2017)
Jumps
*Key People: Invitae
Finance & Acquisitions: Invitae